Evaluation of Clinicopathologic Factors and Surgery Management on Borderline Ovarian Tumor Outcomes

Background: Borderline ovarian tumor (BOT) is a tumor most prevalent in young woman with desire to fertility. There are some controversies on the patient characteristic besides to the factors affecting the recurrence rate among different races. Objectives: The aim of this study is to evaluate clinic...

Full description

Saved in:
Bibliographic Details
Published inInternational Journal of Cancer Management Vol. 15; no. 10
Main Authors Shiravani, Zahra, Namazi, Niloofar, Hashemi, Masooumeh, Najib, Fateme Sadat, Hajisafari Tafti, Mojgan
Format Journal Article
LanguageEnglish
Published 01.10.2022
Online AccessGet full text

Cover

Loading…
Abstract Background: Borderline ovarian tumor (BOT) is a tumor most prevalent in young woman with desire to fertility. There are some controversies on the patient characteristic besides to the factors affecting the recurrence rate among different races. Objectives: The aim of this study is to evaluate clinicopathologic features of the tumor to discover the controversies on the topic. Methods: Medical data of the all referred patients to Motahari clinic from January 2010 till October 2020 were recorded. Patient clinicopathologic characteristics affecting on outcome were evaluated. By using SPSS software, data were tested by chi-square and fish exact test. Also, log rank test was used for survival analysis Results: Totally 145 patients were enrolled. 61.4% versus 38.6% of the patients underwent fertility sparing surgery and radical surgery respectively with common characteristics of mostly belong to stage 1A disease (61.8% vs. 66.1%), unilateral (93.3% vs. 89.3%), serous histology (51.7% vs. 66.1%). The characteristics were different in the aspects of age and tumor size. In the aspect of recurrence rate, higher FIGO stage, younger age, tumor size less than 10cm, performing laparoscopy and fertility sparing surgery were with higher rate of recurrence (P-value < 0.05) while histology type of the tumor, lateralization, micropapillary, microinvasion, noninvasive peritoneal implants, receiving adjuvant chemotherapy and performing lymphadenectomy were not statistically significant for recurrence (P-value > 0.05). Two patients had malignant transformation. Conclusions: Fertility sparing surgery was with more recurrence rate in borderline ovarian tumor patients. However, micropapillary, microinvasion were not significantly with higher recurrence rate in our study but they are challenging issues in border line ovarian tumors among different studies. Due to most prevalence of border line ovarian tumors in young women and desire of fertility preservation, we should notice more to clinicopathologic and surgery types affecting on recurrence of BOTs.
AbstractList Background: Borderline ovarian tumor (BOT) is a tumor most prevalent in young woman with desire to fertility. There are some controversies on the patient characteristic besides to the factors affecting the recurrence rate among different races. Objectives: The aim of this study is to evaluate clinicopathologic features of the tumor to discover the controversies on the topic. Methods: Medical data of the all referred patients to Motahari clinic from January 2010 till October 2020 were recorded. Patient clinicopathologic characteristics affecting on outcome were evaluated. By using SPSS software, data were tested by chi-square and fish exact test. Also, log rank test was used for survival analysis Results: Totally 145 patients were enrolled. 61.4% versus 38.6% of the patients underwent fertility sparing surgery and radical surgery respectively with common characteristics of mostly belong to stage 1A disease (61.8% vs. 66.1%), unilateral (93.3% vs. 89.3%), serous histology (51.7% vs. 66.1%). The characteristics were different in the aspects of age and tumor size. In the aspect of recurrence rate, higher FIGO stage, younger age, tumor size less than 10cm, performing laparoscopy and fertility sparing surgery were with higher rate of recurrence (P-value < 0.05) while histology type of the tumor, lateralization, micropapillary, microinvasion, noninvasive peritoneal implants, receiving adjuvant chemotherapy and performing lymphadenectomy were not statistically significant for recurrence (P-value > 0.05). Two patients had malignant transformation. Conclusions: Fertility sparing surgery was with more recurrence rate in borderline ovarian tumor patients. However, micropapillary, microinvasion were not significantly with higher recurrence rate in our study but they are challenging issues in border line ovarian tumors among different studies. Due to most prevalence of border line ovarian tumors in young women and desire of fertility preservation, we should notice more to clinicopathologic and surgery types affecting on recurrence of BOTs.
Author Hashemi, Masooumeh
Hajisafari Tafti, Mojgan
Namazi, Niloofar
Najib, Fateme Sadat
Shiravani, Zahra
Author_xml – sequence: 1
  givenname: Zahra
  orcidid: 0000-0001-5796-2954
  surname: Shiravani
  fullname: Shiravani, Zahra
– sequence: 2
  givenname: Niloofar
  orcidid: 0000-0002-9993-6209
  surname: Namazi
  fullname: Namazi, Niloofar
– sequence: 3
  givenname: Masooumeh
  orcidid: 0000-0002-3298-5612
  surname: Hashemi
  fullname: Hashemi, Masooumeh
– sequence: 4
  givenname: Fateme Sadat
  orcidid: 0000-0003-3396-145X
  surname: Najib
  fullname: Najib, Fateme Sadat
– sequence: 5
  givenname: Mojgan
  orcidid: 0000-0001-7352-9341
  surname: Hajisafari Tafti
  fullname: Hajisafari Tafti, Mojgan
BookMark eNo1kMtOAjEARRuDiYis_IHuzWiftF0qATTBsBATd5NOH1gz05J2hoS_F4Ku7t2cszi3YBRTdADcY_TIJSZP4cd0FcZMYXQFxoRTWTElvkb_nxFyA6alhAZRhJjgiI-BWRx0O-g-pAiTh_M2xGDSXvffqU27YOBSmz7lAnW08GPIO5eP8F1HvXOdiz08YS8pW5dPoIObg85BR7gdupThZuhN6ly5A9det8VN_3YCPpeL7fy1Wm9Wb_PndWUIkX3lvMZKKMIEsVrMqGKeC-tmTjXeUdlY1hDJnSSWUD4T0iJPufJU0kYwrymdgIeL1-RUSna-3ufQ6XysMarPiepzovqSiP4C4yBdcg
Cites_doi 10.1016/j.ygyno.2020.02.007
10.1016/j.bpobgyn.2011.12.006
10.1186/s12885-020-07262-w
10.1016/j.fertnstert.2020.07.043
10.20471/acc.2019.58.01.04
10.1093/humrep/dez307
10.1016/j.ejso.2019.11.001
10.1111/IGC.0b013e3181a84699
10.1186/s12885-018-4932-2
10.1007/s00404-014-3364-8
10.1016/j.jmig.2020.08.018
10.1016/s1470-2045(11)70288-1
10.1200/jco.2001.19.10.2658
10.2147/cmar.s250394
10.1111/1471-0528.13840
10.1016/j.ygyno.2011.08.008
10.1093/annonc/mdu139
10.1016/j.dib.2020.105653
10.1016/j.ygyno.2010.11.016
10.1111/jog.14210
10.1080/01443615.2018.1499076
10.1080/00016340801995640
10.1111/aogs.14013
10.1007/s00404-017-4496-4
10.1007/s00404-020-05716-x
10.1111/1471-0528.14598
10.3332/ecancer.2020.1031
10.3892/ol.2014.2758
ContentType Journal Article
DBID AAYXX
CITATION
DOI 10.5812/ijcm-114910
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef
DeliveryMethod fulltext_linktorsrc
EISSN 2538-497X
ExternalDocumentID 10_5812_ijcm_114910
GroupedDBID AAYXX
ALMA_UNASSIGNED_HOLDINGS
CITATION
M~E
ID FETCH-LOGICAL-c228t-efa19792472da76394f57de6e9bfe38bd4b285e82d235678d0f359f383b74fa33
ISSN 2538-4422
IngestDate Fri Aug 23 01:57:32 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 10
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c228t-efa19792472da76394f57de6e9bfe38bd4b285e82d235678d0f359f383b74fa33
ORCID 0000-0002-3298-5612
0000-0002-9993-6209
0000-0001-7352-9341
0000-0003-3396-145X
0000-0001-5796-2954
OpenAccessLink https://brieflands.com/articles/ijcm-114910.pdf
ParticipantIDs crossref_primary_10_5812_ijcm_114910
PublicationCentury 2000
PublicationDate 2022-10-01
PublicationDateYYYYMMDD 2022-10-01
PublicationDate_xml – month: 10
  year: 2022
  text: 2022-10-01
  day: 01
PublicationDecade 2020
PublicationTitle International Journal of Cancer Management
PublicationYear 2022
References key-A114910REF27-27
key-A114910REF25-25
key-A114910REF1-1
key-A114910REF2-2
key-A114910REF3-3
key-A114910REF4-4
key-A114910REF12-12
key-A114910REF10-10
key-A114910REF18-18
key-A114910REF14-14
key-A114910REF16-16
key-A114910REF23-23
key-A114910REF21-21
key-A114910REF26-26
key-A114910REF28-28
key-A114910REF24-24
key-A114910REF13-13
key-A114910REF5-5
key-A114910REF11-11
key-A114910REF17-17
key-A114910REF6-6
key-A114910REF15-15
key-A114910REF7-7
key-A114910REF19-19
key-A114910REF8-8
key-A114910REF9-9
key-A114910REF22-22
key-A114910REF20-20
References_xml – ident: key-A114910REF2-2
  doi: 10.1016/j.ygyno.2020.02.007
– ident: key-A114910REF4-4
  doi: 10.1016/j.bpobgyn.2011.12.006
– ident: key-A114910REF24-24
  doi: 10.1186/s12885-020-07262-w
– ident: key-A114910REF25-25
  doi: 10.1016/j.fertnstert.2020.07.043
– ident: key-A114910REF14-14
  doi: 10.20471/acc.2019.58.01.04
– ident: key-A114910REF5-5
  doi: 10.1093/humrep/dez307
– ident: key-A114910REF7-7
  doi: 10.1016/j.ejso.2019.11.001
– ident: key-A114910REF27-27
  doi: 10.1111/IGC.0b013e3181a84699
– ident: key-A114910REF19-19
  doi: 10.1186/s12885-018-4932-2
– ident: key-A114910REF20-20
  doi: 10.1007/s00404-014-3364-8
– ident: key-A114910REF26-26
  doi: 10.1016/j.jmig.2020.08.018
– ident: key-A114910REF23-23
  doi: 10.1016/s1470-2045(11)70288-1
– ident: key-A114910REF28-28
  doi: 10.1200/jco.2001.19.10.2658
– ident: key-A114910REF1-1
  doi: 10.2147/cmar.s250394
– ident: key-A114910REF10-10
  doi: 10.1111/1471-0528.13840
– ident: key-A114910REF8-8
  doi: 10.1016/j.ygyno.2011.08.008
– ident: key-A114910REF22-22
  doi: 10.1093/annonc/mdu139
– ident: key-A114910REF17-17
  doi: 10.1016/j.dib.2020.105653
– ident: key-A114910REF12-12
  doi: 10.1016/j.ygyno.2010.11.016
– ident: key-A114910REF6-6
  doi: 10.1111/jog.14210
– ident: key-A114910REF11-11
  doi: 10.1080/01443615.2018.1499076
– ident: key-A114910REF9-9
  doi: 10.1080/00016340801995640
– ident: key-A114910REF18-18
  doi: 10.1111/aogs.14013
– ident: key-A114910REF13-13
  doi: 10.1007/s00404-017-4496-4
– ident: key-A114910REF15-15
  doi: 10.1007/s00404-020-05716-x
– ident: key-A114910REF16-16
  doi: 10.1111/1471-0528.14598
– ident: key-A114910REF3-3
  doi: 10.3332/ecancer.2020.1031
– ident: key-A114910REF21-21
  doi: 10.3892/ol.2014.2758
SSID ssib030047505
ssib044740538
Score 2.251586
Snippet Background: Borderline ovarian tumor (BOT) is a tumor most prevalent in young woman with desire to fertility. There are some controversies on the patient...
SourceID crossref
SourceType Aggregation Database
Title Evaluation of Clinicopathologic Factors and Surgery Management on Borderline Ovarian Tumor Outcomes
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9tAEF6l9NJLRQVVH1DtgVvkEPaR9R4LSoSQIIckUsQlWtu7IlETV8bhwIGfwG_u7CO2U3IALlZkeS0n82Xmm_U3MwidQIzvMa16kTS2JEcI8IOC0ijjsUi6OpWxGzZxfdO7nLCrKZ-2Ws8N1dK6TDrp4866kvdYFc6BXW2V7BssW90UTsBnsC8cwcJwfJWN-1WrbqeqcEWOuZ0x7D1aexCG6Th5pq9_buhd7HuCc9d601HN4QOkzfBvH6-XedEerkt44iAwXNRy9-3dw0BlLyx0ih1SmtHdvFAPfmxU-1bdFVUQuFFL9Tj3WPyT50YVtS-8t00MfCHRfZ6D86y3rNVi7l4gDYAiL3V7pDJVNjcuIOfdSOCCfyPW1zLmy5I7unFOiumWg-ZNIHZ3OX4OPAWsNV-kEFgg6QtS2a322v-FvUqMCGmQXT6zi2d-8Qf0kQjJrUT0-qm_8U-2ORkQrMr_MSaA7rph6dV38SWg9n6njYdpkJ4Gexnvo8_BVvi3x9AX1NKrA5TW-MG5wS_wgwN-MOAHB_zg2sgYltX4wQE_2OEHb_BziCaD_vjiMgpDN6KUkLiMtFFnUkBWLkimIPhIZrjIdE_LxGgaJxlLSMx1TDJCOTCdrGsol4bGNBHMKEq_or1VvtLfELbtAOE6TiTwxEydxcqkjCob1xiHtOE7Otn8KrO_vrfKbIcxfrzusp_oU42yI7RXFmt9DISxTH45K_4DBjpvJA
link.rule.ids 315,786,790,27955,27956
linkProvider ISSN International Centre
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+Clinicopathologic+Factors+and+Surgery+Management+on+Borderline+Ovarian+Tumor+Outcomes&rft.jtitle=International+Journal+of+Cancer+Management&rft.au=Shiravani%2C+Zahra&rft.au=Namazi%2C+Niloofar&rft.au=Hashemi%2C+Masooumeh&rft.au=Najib%2C+Fateme+Sadat&rft.date=2022-10-01&rft.issn=2538-4422&rft.eissn=2538-497X&rft.volume=15&rft.issue=10&rft_id=info:doi/10.5812%2Fijcm-114910&rft.externalDBID=n%2Fa&rft.externalDocID=10_5812_ijcm_114910
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2538-4422&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2538-4422&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2538-4422&client=summon